• Male or female, Age 18-65 years old; negative results of serum or urine pregnancy test within 48 hours before treatment are needed to provide for fertile women (or women who have undergone sterilization or at least 2 years after menopause can be regarded as infertile);

• Patients diagnosed as ovarian cancer, non-small cell lung cancer, breast cancer, gastric cancer, etc., accompanied by serous cavity metastasis, have received systemic standard treatment, and have clinical symptoms of serous cavity metastasis;

• The Eastern Cooperative Oncology Group (ECOG) performance status score is 0-2;

• Estimated life expectancy ≥ 3 months (according to investigator's judgement);

• Absolute neutrophil count ≥ 1.5×10\^9/L, platelet count ≥ 90×10\^9/L, absolute lymphocyte count ≥1×10\^8/L, hemoglobin ≥ 9.0 g/dL;

• Creatinine clearance rate ≥60 mL/min, Serum ALT/AST≤2.5 times of the normal level, and total bilirubin≤1.5 times of the normal level;

• Cardiac ejection fraction ≥50%, no pericardial effusion;

• No other serious diseases (autoimmune diseases or any immune deficiency disease or other disease in need of immunosuppressive therapy);

• Patients must stop chemotherapy and targeted therapy for at least 3 weeks before starting treatment;

⁃ Patients must take reliable contraceptive measures before entering the trial, during the research process until 1 year after CAR-T infusion; reliable contraceptive measures will be determined by the main investigator or designated personnel;

⁃ Voluntarily participate in the research, understand and sign the informed consent;

⁃ The side effect of the last anti-tumor treatment was reduced to ≤1 grade, except for hair loss.